Our study contributes to a growing body of research implicating hepatic endocannabinoid signaling in regulating metabolic function by showing that hepatocyte CB1r is necessary for hormonal disruption and dyslipidemia, but not weight gain, following ECD. This evidence concerns the gene CNR1 and metabolic syndrome.